Royal Bank of Canada’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $63.7M | Buy |
+1,050,000
| New | +$61.2M | 0.01% | 807 |
|
|
2025
Q4 | – | Sell |
-20,000
| Closed | -$902K | – | 7173 |
|
|
2025
Q3 | $902K | Buy |
+20,000
| New | +$934K | ﹤0.01% | 4069 |
|
|
2024
Q4 | – | Sell |
-475,000
| Closed | -$24.6M | – | 6902 |
|
|
2024
Q3 | $24.6M | Buy |
+475,000
| New | +$22.3M | 0.01% | 1225 |
|
|
2022
Q4 | – | Sell |
-65,000
| Closed | -$4.62M | – | 7230 |
|
|
2022
Q3 | $4.62M | Sell |
65,000
-357,500
| -85% | -$25.9M | ﹤0.01% | 2133 |
|
|
2022
Q2 | $32.5M | Sell |
422,500
-1,771,300
| -81% | -$135M | 0.01% | 841 |
|
|
2022
Q1 | $160M | Buy |
2,193,800
+1,088,000
| +98% | +$73.1M | 0.04% | 354 |
|
|
2021
Q4 | $68.9M | Buy |
+1,105,800
| New | +$64.9M | 0.02% | 668 |
|
|
2020
Q1 | – | Sell |
-620,000
| Closed | -$39.8M | – | 6676 |
|
|
2019
Q4 | $39.8M | Buy |
620,000
+520,000
| +520% | +$29.8M | 0.01% | 735 |
|
|
2019
Q3 | $5.07M | Sell |
100,000
-50,000
| -33% | -$2.35M | ﹤0.01% | 2071 |
|
|
2019
Q2 | $6.8M | Sell |
150,000
-107,500
| -42% | -$5.01M | ﹤0.01% | 1848 |
|
|
2019
Q1 | $12.3M | Buy |
257,500
+145,600
| +130% | +$7.25M | 0.01% | 1371 |
|
|
2018
Q4 | $5.82M | Buy |
111,900
+100,100
| +848% | +$5.38M | ﹤0.01% | 1870 |
|
|
2018
Q3 | $733K | Sell |
11,800
-67,900
| -85% | -$4.03M | ﹤0.01% | 3619 |
|
|
2018
Q2 | $4.41M | Buy |
+79,700
| New | +$4.3M | ﹤0.01% | 2104 |
|
|
2018
Q1 | – | Sell |
-127,400
| Closed | -$7.81M | – | 6348 |
|
|
2017
Q4 | $7.81M | Sell |
127,400
-63,500
| -33% | -$3.97M | ﹤0.01% | 1772 |
|
|
2017
Q3 | $12.2M | Sell |
190,900
-360,100
| -65% | -$21M | 0.01% | 1397 |
|
|
2017
Q2 | $30.7M | Sell |
551,000
-148,500
| -21% | -$8.08M | 0.02% | 786 |
|
|
2017
Q1 | $38M | Buy |
699,500
+595,700
| +574% | +$32.7M | 0.02% | 650 |
|
|
2016
Q4 | $6.07M | Sell |
103,800
-18,900
| -15% | -$1.03M | ﹤0.01% | 1828 |
|
|
2016
Q3 | $6.62M | Buy |
122,700
+26,900
| +28% | +$1.73M | ﹤0.01% | 1728 |
|
|
2016
Q2 | $7.05M | Sell |
95,800
-512,900
| -84% | -$36.2M | ﹤0.01% | 1681 |
|
|
2016
Q1 | $38.9M | Buy |
608,700
+556,200
| +1,059% | +$35.1M | 0.02% | 571 |
|
|
2015
Q4 | $3.61M | Buy |
52,500
+42,500
| +425% | +$2.81M | ﹤0.01% | 2077 |
|
|
2015
Q3 | $592K | Hold |
10,000
| – | – | ﹤0.01% | 3341 |
|
|
2015
Q2 | $665K | Hold |
10,000
| – | – | ﹤0.01% | 3309 |
|
|
2015
Q1 | $645K | Hold |
10,000
| – | – | ﹤0.01% | 3268 |
|
|
2014
Q4 | $590K | Sell |
10,000
-90,000
| -90% | -$5.08M | ﹤0.01% | 3391 |
|
|
2014
Q3 | $5.12M | Hold |
100,000
| – | – | ﹤0.01% | 1634 |
|
|
2014
Q2 | $4.85M | Buy |
+100,000
| New | +$4.93M | ﹤0.01% | 1677 |
|
|
2013
Q3 | – | Sell |
-20,000
| Closed | -$894K | – | 6083 |
|
|
2013
Q2 | $894K | Buy |
+20,000
| New | +$868K | ﹤0.01% | 2662 |
|
Other funds holding BMY
VCM
VPM
Royal Bank of Canada's BMY Position: Q1 2026 in Review
Royal Bank of Canada reduced its Bristol-Myers Squibb (BMY) stake by 13% in Q1 2026, selling an estimated $98.2M and leaving 10,958,702 shares worth $665M. The position accounts for 0.12% of the portfolio, ranked #167.
Royal Bank of Canada first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $816M in Q1 2025. 2,528 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Royal Bank of Canada held 10,958,702 shares of Bristol-Myers Squibb worth $665M as of Q1 2026.
- Royal Bank of Canada sold 1,684,783 Bristol-Myers Squibb shares in Q1 2026, an estimated $98.2M.
- Bristol-Myers Squibb made up 0.12% of Royal Bank of Canada's portfolio in Q1 2026, its #167 holding.
- Royal Bank of Canada first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
- Royal Bank of Canada's Bristol-Myers Squibb position peaked at $816M in Q1 2025.
- 2,528 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.